Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial

  title={Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial},
  author={Bruno François and Xavier Wittebole and Ricard Ferrer and Jean Paul Mira and Thierry Dugernier and Sebastien Gibot and Marc Derive and Aur{\'e}lie Olivier and Val{\'e}rie Cuvier and Stephan Witte and Peter Pickkers and François Vandenhende and Jean Jacques Garaud and Miguel S{\'a}nchez and Margarita Salcedo-Magguilli and Pierre-François Laterre},
  journal={Intensive Care Medicine},
Purpose Nangibotide is a specific TREM-1 inhibitor that tempered deleterious host–pathogens interactions, restored vascular function, and improved survival, in animal septic shock models. This study evaluated the safety and pharmacokinetics of nangibotide and its effects on clinical and pharmacodynamic parameters in septic shock patients. Methods This was a multicenter randomized, double-blind, two-stage study. Patients received either continuous infusion of nangibotide (0.3, 1.0, or 3.0 mg/kg… 

New Agents in Development for Sepsis: Any Reason for Hope?

Within the entire sepsis drugs portfolio, those targeting the immune response are probably the most promising, and monoclonal antibodies targeting either cytokines or infectious agents are undoubtedly part of the potential successful therapeutic classes to come.

Soluble triggering receptor expressed on myeloid cells-1 is a marker of organ injuries in cardiogenic shock: results from the CardShock Study

High levels of circulating Triggering Receptor Expressed on Myeloid cells-1 (TREM-1), were associated with death in acute myocardial infarction confirming excessive inflammation as determinant of bad outcome.

sTREM-1 is a specific biomarker of TREM-1 pathway activation

The results suggest that sTREM-1 release depends on the activation and dimerization of the receptor and is a marker of TREM- 1 receptor activation, which is a key step in allowing its activation and the transduction of intracellular signals.

Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?

  • M. RatainI. TannockA. Lichter
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2021
Most new targeted anticancer agents are still tested in early clinical trials to determine the maximum tolerated dose and that dose is carried forward into late-stage studies, despite an understanding of these principles.

TREM-1 isoforms in bacterial infections: to immune modulation and beyond

An updated insight is provided into how the receptor influences and is influenced by bacterial infections, highlighting the advances regarding the use/manipulation of TREM-1 isoforms in biomedical research and clinical practice.

Review of potential medical treatments for middle ear cholesteatoma

Middle ear cholesteatoma (MEC), is a destructive, and locally invasive lesion in the middle ear driven by inflammation with an annual incidence of 10 per 100,000. Surgical extraction/excision remains

Relationships Between Age, Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1), and Mortality Among Critically Ill Adults: A Cohort Study

Supplemental Digital Content is available in the text ABSTRACT Background: Innate immune dysregulation may contribute to age-related differences in outcomes among critically ill adults. Soluble

TREM-1 Modulation Strategies for Sepsis

This review encompasses the ligands investigated as activators of TREM-1 thus far and highlights the development and efficacy of novel inhibitors for the treatment of sepsis and septic shock.

Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives

This review wants to report the update on these novel APIs, focusing on the molecules in clinical development, representing the direct consequence of the drug discovery process of the last 10 years.



Drotrecogin alfa (activated) in adults with septic shock.

DrotAA did not significantly reduce mortality at 28 or 90 days, as compared with placebo, in patients with septic shock, and rates of death at 28 and 90 days were not significantly different in other predefined subgroups, including patients at increased risk for death.

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

Among patients with severe sepsis, the use of eritoran, compared with placebo, did not result in reduced 28-day mortality, and no significant differences were observed in any of the prespecified subgroups.

Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial.

This is the first trial of an immunoadjuvant therapy targeting defects in adaptive immunity in patients with sepsis and CYT107 reversed the marked loss of CD4+ and CD8+ immune effector cells, a hallmark of septic shock and a likely key mechanism in its morbidity and mortality.

Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial

Rationale: There remains uncertainty about the role of corticosteroids in sepsis with clear beneficial effects on shock duration, but conflicting survival effects. Two transcriptomic sepsis response

Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial.

Among patients with sepsis-associated coagulopathy, administration of a human recombinant thrombomodulin, compared with placebo, did not significantly reduce 28-day all-cause mortality.

Effects of a TREM-Like Transcript 1–Derived Peptide During Hypodynamic Septic Shock in Pigs

Cardiovascular failure was dampened as attested by a better mean arterial pressure, cardiac index, cardiac power index, and SvO2, despite lower norepinephrine requirements.

Time course of immature platelet count and its relation to thrombocytopenia and mortality in patients with sepsis

Thrombopoietic activity was generally maintained in the acute phase of sepsis, and a decrease in AIPC after admission was independently associated with the development of severe thrombocytopenia and mortality, suggesting the importance of suppressed throm bopoiesis in the pathophysiology of septicaemia.

Soluble TREM-1 Serum Level can Early Predict Mortality of Patients with Sepsis, Severe Sepsis and Septic Shock

Early prognostic prediction of sepsis is essential in adjusting therapeutic protocols to prevent deterioration and reduce mortality. We compared the predictive value of the serum concentration of the

Attenuation of Responses to Endotoxin by the Triggering Receptor Expressed on Myeloid Cells-1 Inhibitor LR12 in Nonhuman Primate

The triggering receptor expressed on myeloid cells-1 inhibitor LR12 is able to mitigate endotoxin-associated clinical and biological alterations, with no obvious side effects, which paves the way for future phases Ia and Ib trials in humans.